First Tracks Biotherapeutics to release Phase 1b cohort 1 data for ANB033 in celiac disease Oct. 12

• First Tracks Biotherapeutics will release top-line Cohort 1 data from its Phase 1b ANB033 celiac disease trial on Oct. 12, 2026.
• Results have not been presented yet; the company plans a morning press release followed by an investor call and webcast.
• Cohort 1 is a gluten-challenge study designed to assess whether ANB033 can prevent intestinal tissue damage.
• The readout is an early clinical catalyst for ANB033, a CD122 antagonist being developed for celiac disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. First Tracks Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610111600PRIMZONEFULLFEED9843542) on October 11, 2026, and is solely responsible for the information contained therein.